GlassScriptPhysician profile
Lisa Haut
NPI 1962400150
$13,088.37
in general payments reported to CMS, 2019-2025
27 companies · $3,904 in 2025
The $3,904 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,881 · 2022: $1,553 · 2023: $2,107 · 2024: $3,644 · 2025: $3,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,552 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,551.91 |
| Education | $103.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,486.15 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,327.43 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,324.76 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $1,143.57 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $736.75 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $731.89 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $557.60 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $374.44 | 2023-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $342.25 | 2023-2025 | Rexulti |
| Gilead Sciences, INC. | $326.33 | 2021-2025 | Epclusa |
| Indivior INC. | $308.33 | 2022-2025 | Sublocade |
| Novo Nordisk INC | $262.17 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $232.30 | 2023-2025 | Auvelity, Sunosi |
| Uswm, LLC | $227.50 | 2021-2024 | Lucemyra, Zimhi |
| Takeda Pharmaceuticals U.S.A., INC. | $209.67 | 2021-2025 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $86.33 | 2021-2024 | Qelbree, Qelbree |
| Braeburn INC. | $82.25 | 2023-2025 | Brixadi |
| Astrazeneca Pharmaceuticals LP | $68.15 | 2022-2023 | Breztri |
| Sunovion Pharmaceuticals INC. | $66.79 | 2021 | |
| Lilly USA, LLC | $55.18 | 2023-2024 | Mounjaro, Zepbound, Trulicity |
| Regeneron Healthcare Solutions, INC. | $27.25 | 2023 | Dupixent |
| Almatica Pharma LLC | $24.74 | 2021 | |
| Ardelyx, INC. | $22.68 | 2023 | Ibsrela |
| Jazz Pharmaceuticals INC. | $18.79 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.07 | 2023 | Jornay Pm |
| Insulet Corporation | $14.61 | 2023 | Omnipod |
| Pfizer INC. | $14.39 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Haut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.